Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: What is the true direction of effect?

Journal of Rheumatology

Volumn 32, Issue 10, 2005, Pages 1856-1862

  Davis III, John M ^a   Maradit Kremers, Hilal ^a   Gabriel, Sherine E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DIURETIC AGENT; GLUCOCORTICOID; GLYCOSIDE; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; EDITORIAL; HEART FAILURE; HEART INFARCTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LONG TERM CARE; LOW DRUG DOSE; MORBIDITY; NONHUMAN; PATHOGENESIS; PATIENT EDUCATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HUMANS; MORBIDITY; RHEUMATOLOGY; RISK ASSESSMENT;

EID: 26444519878     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (55)

1. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-73.
2. Wolfe F. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003;30:36-40.
3. Nicola P, Maradit Kremers H, Roger V, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005;52:412-20.
4. Bijlsma JW, Boers M, Saag KG, Furst DE. Glucocorticoids in the treatment of early and late RA. Ann Rheum Dis 2003;62:1033-7.
5. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
6. del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiovascular risk factors. Arthritis Rheum 2001;44:2737-45.
7. Maradit-Kremers H, Crowson C, Nicola P, et al. Increased unrecognized coronary heart disease in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005;52:402-11.
8. Maradit Kremers H, Nicola P, Crowson C, Ballman K, Gabriel S. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:412-20.
9. Maradit Kremers H, Crowson C, Nicola P, Ballman KV, Gabriel S. Erythrocyte sedimentation rate (ESR) and congestive heart failure (CHF) in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2004;50 Suppl:S557-S58.
10. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002;29:62-7.
11. Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med J 1994;70:863-70.
12. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999;26:2562-71.
13. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
14. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305-11.
15. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004;351:2611-8.
16. Nashel DJ. Is atherosclerosis a complication of long-term corticosteroid treatment? Am J Med 1986;80:925-9.
17. Raynauld JP. Cardiovascular mortality in rheumatoid arthritis: how harmful are corticosteroids [editorial]? J Rheumatol 1997;24:415-6.
18. Girod JP, Brotman DJ. Does altered glucocorticoid homeostasis increase cardiovascular risk? Cardiovasc Res 2004;64:217-26.
19. Stamler J, Pick R, Katz L. Effects of cortisone, hydrocortisone and corticotropin on lipemia, glycemia and atherogenesis in cholesterol-fed chicks. Circulation 1954;10:237-46.
20. Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999;84:2664-72.
21. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine 1989;68:141-50.
22. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 1975;58:243-64.
23. Jefferys D, Lessof M, Mattock M. Corticosteroid treatment, serum lipids and coronary artery disease. Postgrad Med J 1980;56:491-3.
24. Stern MP, Kolterman OG, Fries JF, McDevitt HO, Reaven GM. Adrenocortical steroid treatment of rheumatic diseases. Arch Int Med 1973;132:97-101.
25. Kalbak K. Incidence of arteriosclerosis in patients with rheumatoid arthritis receiving long-term corticosteroid therapy. Ann Rheum Dis 1972;31:196-200.
26. Wei L, MacDonald T, Walker B. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Int Med 2004;141:764-70.
27. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004;90:859-65.
28. Wolfe F, Michaud K. Corticosteroids increase the risk of diabetes mellitus in RA and contribute to the risk of myocardial infarction and heart failure [abstract]. Ann Rheum Dis 2004;63 Suppl:SAT0379.
29. Wolfe F, Michaud K. Prednisone but not biologies or DMARDs is associated with increased risk of myocardial infarction in persons with RA [abstract]. Ann Rheum Dis 2004;63 Suppl:OP0039.
30. Suissa S, Bernatsky S, Hudson M, Kezouh A. DMARD use and the risk of acute myocardial infarction in rheumatoid arthritis [abstract]. Ann Rheum Dis 2004;63 Suppl:OP0038.
31. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology Oxford 2005;44:677-80.
32. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997;24:445-51.
33. McMahon A. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf 2003;12:551-8.
34. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002;29:1015-22.
35. Erkan D, Yazici Y, Harrison MJ, Paget SA. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy. Arthritis Care Res 2002;47:285-90.
36. del Rincon I, O'Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004;50:3813-22.
37. Park YB, Ahn CW, Choi HK, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002;46:1714-9.
38. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63.
39. Svenson KL, Lundqvist G, Wide L, Hallgren R. Impaired glucose handling in active rheumatoid arthritis: effects of corticosteroids and antirheumatic treatment. Metabolism 1987;36:944-8.
40. Hallgren R, Berne C. Glucose intolerance in patients with chronic inflammatory diseases is normalized by glucocorticoids. Acta Med Scand 1983;213:351-5.
41. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-a- and obesity-induced insulin resistance. Science 1996;271:665-8.
42. Svenson KL, Lithell H, Hallgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. Arch Intern Med 1987;147:1917-20.
43. Boers M, Nurmohamed MT, Doelman CJA, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:842-5.
44. Asanuma Y, Kawai S, Aoshima H, Kaburaki J, Mizushima Y. Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum 1999;42:443-7.
45. Manicourt DH, Triki R, Fukuda K, Devogelaer JP, Nagant de Deuxchaiznes C, Thonar EJ. Levels of circulating tumor necrosis factor alpha and interleukin 6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum 1993;36:490-9.
46. Wong M, Toh L, Wilson A, et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003;48:81-9.
47. Tchetverikov I, Ronday HK, van El B, et al. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis 2004;63:881-3.
48. Youssef PP, Triantafillou S, Parker A, et al. Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis. Reduced E-selectin and intercellular adhesion molecule 1 expression. Arthritis Rheum 1996;39:1970-9.
49. Youssef PP, Haynes DR, Triantafillou S, et al. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum 1997;41:761-7.
50. Lazzerini P, Capecchi PL, Bisogno S, Galeazzi M, Marcolongo R, Pasini FL. Reduction in plasma homocysteine level in patients with rheumatoid arthritis given pulsed glucocorticoid treatment. Ann Rheum Dis 2003;62:694-5.
51. Yki-Jarvinen H, Bergholm R, Leirisalo M. Increased inflammatory activity parallels increased basal nitric oxide production and blunted response to nitric oxide in vivo in rheumatoid arthritis. Ann Rheum Dis 2003;62:630-4.
52. Bergholm R, Leirisalo-Repo M, Vehkavaara S, Makimattila S, Taskinen MR, Yki-Jarvinen H. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002;22:1637-41.
53. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004;141:47-56.
54. Jacobsson LT, Knowler WC, Pillemer S, et al. Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians. Arthritis Rheum 1993;36:1045-53.
55. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.